Dabrafenib plus trametinib in an elderly patient with BRAF V600E-mutant advanced pancreatic adenocarcinoma: A case report.

Despite the success of anti- therapy in melanoma, data from randomized clinical trials are lacking for targeted therapy against mutations-typically the V600E variant-in pancreatic adenocarcinoma, which is associated with a poor prognosis under traditional cytotoxic chemotherapy. Here, we report a case of an elderly patient with advanced pancreatic adenocarcinoma harboring a V600E mutation who received low-dose dabrafenib and trametinib and achieved satisfactory clinical outcomes. We describe a 78-year-old female with V600E-mutant pancreatic adenocarcinoma. The patient was diagnosed with AJCC clinical stage IV (cT3N2M1) pancreatic adenocarcinoma and she declined chemotherapy because of her advanced age. Owing to the V600E mutation, the patient was started on combined - and inhibitors (dabrafenib/trametinib). CT scans showed PR on 31 December 31, 2024, and repeated CT scans showed SD on May 2025. At the time of drafting this report, the patient had achieved 8 months of PFS. This case suggests that dose-adjusted dabrafenib combined with trametinib might be a potentially effective treatment strategy for elderly patients with advanced pancreatic adenocarcinoma harboring V600E mutations.